See the DrugPatentWatch profile for Clenpiq
What is Clenpiq?
Clenpiq is a prescription medication used for colonoscopy preparation. It is an oral solution that is administered in two doses [1].
What are Clenpiq's clinical trial results?
The efficacy of Clenpiq in preparing patients for colonoscopy was evaluated in two multicenter, randomized, parallel-group trials. These trials involved a total of 1,104 adult patients. In both studies, Clenpiq demonstrated non-inferiority to a comparator product in achieving adequate bowel preparation, which is defined as the ability to visualize the colonic mucosa [1].
Specifically, in the first trial, 87.1% of patients receiving Clenpiq had successful bowel preparation compared to 84.6% in the comparator group. In the second trial, 87.8% of patients on Clenpiq achieved adequate preparation, versus 84.5% in the comparator group. These results indicate that Clenpiq is effective for its intended use [1].
The most common adverse reactions reported in clinical trials for Clenpiq included nausea, vomiting, headache, and abdominal distension. Most of these events were mild to moderate in severity [1].
How is Clenpiq administered?
Clenpiq is taken in two separate doses. The first dose is taken the evening before the colonoscopy, and the second dose is taken on the morning of the procedure, at least 2 hours before the scheduled examination [1].
What are the safety concerns with Clenpiq?
Clenpiq is contraindicated in patients with gastrointestinal obstruction, gastric retention, ileus, toxic colitis, or toxic megacolon. It is also not recommended for patients with severe renal impairment or congestive heart failure. Patients should be advised to hydrate adequately before, during, and after the use of Clenpiq to prevent dehydration [1].
When does Clenpiq's patent expire?
Information regarding the specific patent expiration dates for Clenpiq is not publicly available in the provided text. Patent information for pharmaceuticals can be found through resources like DrugPatentWatch.com [2].